Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 14, 2013; 19(38): 6315-6318
Published online Oct 14, 2013. doi: 10.3748/wjg.v19.i38.6315
Published online Oct 14, 2013. doi: 10.3748/wjg.v19.i38.6315
Epidermal growth factor receptor and metastatic colorectal cancer: Insights into target therapies
Ramon Andrade de Mello, António Araújo, Department of Medical Oncology, Portuguese Oncology Institute, 4200-072 Porto, Portugal
Ramon Andrade de Mello, Department of Medicine, FMUP-Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
Andrea Marin Marques, Department of Medicine, Centro Hospitalar Médio Ave, 4780 Porto, Portugal
Author contributions: All authors contributed as the same for this manuscript preparation.
Correspondence to: Ramon Andrade de Mello, MD, PhD, Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ramondemello@gmail.com
Telephone: +351-22-584000 Fax: +351-22-584010
Received: May 18, 2013
Revised: August 4, 2013
Accepted: September 4, 2013
Published online: October 14, 2013
Revised: August 4, 2013
Accepted: September 4, 2013
Published online: October 14, 2013
Core Tip
Core tip: Metastatic colorectal cancer (mCRC) remains a challenge for oncologists worldwide. Despite a very aggressive disease profile, mCRC’s outcomes are improving toward last decades. Target drugs, such as cetuximab and panitumumab, acquired a main role in this scenario whether phase III trials showed interesting results in overall survival and disease control. Thus, we will briefly in this paper discuss some issues and pitfalls concerning this framework.